Key Drivers
- Margin Expansion
- Strong Liquidity
- Premium Valuation
AIAI Summary
KN has shifted from a low-quality cyclical component story to a higher-quality mix-and-margin story, but with the stock already pricing in that improvement, the key investment test is whether medtech wins like Elucent can translate into sustained free cash flow and margin expansion rather than a one-quarter re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Liquidity
- •Premium Valuation
KN shows improving margins, solid cash generation, and strong liquidity, but its high valuation, intangible-heavy balance sheet, and only moderate capital returns make the stock look demanding.
Price Behavior
Key Price Behavior Insights:
- •Sharp rebound
- •Range-bound pause
- •Key resistance
KN remains constructive over the last month after a sharp rebound from late-July lows, but it is consolidating below $39.5-$40.4 and needs to hold the high-$37s/$37.0-$37.5 support to keep the uptrend intact.
Sharp jump from $34.56 on 2026-07-29 to $40.40 on 2026-08-04
Sentiment & News
Key News Insights:
- •Earnings beat
- •Medtech win
- •Margin expansion
Knowles delivered an earnings beat, secured a medtech manufacturing win, and saw improved sentiment as strong operating trends and guidance momentum drove the stock higher.
The recent news flow is positive for Knowles, reinforcing improving fundamentals and supporting near-term upside momentum
Similar Companies in Technology
Other companies in the same sector with AI ratings